Elan Pharmaceuticals, Inc.

Other

Wyeth

Merck + Co., Inc.

Eli Lilly and Company

Athena Neurosciences, Inc.

Genentech, Inc.

Elan Corporation, Plc

Eli Lilly Company

Eugene D Thorsett

Michael A Pleiss

Andrei William Konradi

Francine S Grant

Christopher Michael Semko

Darren B Dressen

Varghese John

Lee H Latimer

Jeffrey S Nissen

Dimitrios Sarantakis

Anthony Frank Kreft

Susan Ashwell

Jing Wu

Thomas Edward Mabry

Ying-Zi Xu

Warren Jaye Porter

Jay S Tung

Jon Kevin Reel

James Joseph Droste

James E Audia

Thomas Charles Britton

Gregory Scott Welmaker

William Leonard Scott

Louis John Lombardo

Bruce Anthony Dressman

Russell Dean Stucky

Elbert E Harris

Michael S Dappen

Steven Scott Henry

Stephen B Freedman

James A Audia

Arthur A Patchett

Reinhardt Bernhard Baudy

Stacey L McDaniel

Beverly K Folmer

R Jeffrey Neitz

Cynthia L Cwi

Frank Stappenbeck

Lawrence Y Fang

Jenifer Lea Smith

George W Huffman

Brian P Stupi

Louis Brogley

Christopher Joseph Soares

Jon Eric Hawkinson

Clark Norman Eid

Michael Ye

Sarah Bartulis

Ramesh Kasar

William J Greenlee

Gary Paul Stack

Frank P DiNinno

Matthew J Wyvratt

Thomas N Salzmann

John Alan Tucker

Celia A Whitesitt

Kiev S Ly

Christine M Tarby

Dennis Michael Kubrak

Martin Neitzel

Russell E Rydel

Charles William Mann

Ashley C Guinn

Francine S Farouz

Edward W Tristram

Cynthia Y Robinson

Robert Warren Sullivan

Bradley S Johnson

Ryan C Holcomb

Mohammed A Khan

William H Parsons

James V Heck

John P Burnier

Alan L Maycock

Theodore A Yednock

David Taub

Kenneth E Wilson

Gregory Alan Stephenson

Peter L Barker

John Varghese

Joanne M Williamson

Benjamin Alan Diseroad

Michael A Pliess

Yak-Fa Cheung

Brian P Stupl

Dimitrios Sarntakis

Jeffrey Neitz

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4

Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4

Disclosed are sulfonylquinoxalone acetamide derivatives useful as bradykinin antagonists.

Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists

Compounds which inhibit leukocyte adhesion mediated by VLA-4

The present invention provides crystalline (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, a crystalline anydrate and dihydrates thereof, compositions comprising (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, its crystalline anhydrate or dihydrate, and methods for using the same.

Lactam compound

Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4

Disclosed are compounds which bind &#x3b1;integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by &#x3b1;integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

[object Object]

Disclosed are compounds which inhibit &#x3b2;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &#x3b2;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &#x3b2;-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4

Disclosed are compounds which bind &#x3b1;integrins, where the &#x3b1;integrin is preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by &#x3b1;integrins, where the &#x3b1;integrin is preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4

Disclosed are a series of phenylalanine derivatives, to compositions containing them, to processes for their preparation, and to their use in medicine.

Phenylalanine derivatives as alpha 4 integrin inhibitors

Disclosed are compounds which bind VLA-4. Certain of these compounds aslo inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4

Growing community of inventors

Half Moon Bay, CA, United States of America

Eugene D Thorsett